Online citations, reference lists, and bibliographies.

Glycosylation Of Prothrombin Fragment 1 Governs Calcium Oxalate Crystal Nucleation And Aggregation, But Not Crystal Growth

D. Webber, A. Rodgers, E. Sturrock
Published 2007 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Urinary glycoproteins play an important role in the modulation of calcium oxalate crystallisation. In several cases, this has been attributed to glycosylation of the proteins as evidenced by urinary prothrombin fragment 1 where there is a correlation between sialylation and calcium oxalate kidney stone disease. In the present study, plasma-derived prothrombin fragment 1 (PTF1) was enzymatically modified in order to generate its asialo and aglyco forms. The parent glycoprotein and its two glycoforms were used in calcium oxalate crystallisation studies to assess the role of the carbohydrate moeity in PTF1’s potent inhibitory activity. The glycans inhibited crystal aggregation and promoted crystal nucleation, but had no effect on crystal growth. The terminal sialic acid residues had a small effect on inhibition of crystal aggregation whereas they contributed significantly to promotion of nucleation. These results indicate that glycosylation of PTF1 governs calcium oxalate crystal nucleation and aggregation but it does not affect the protein’s role in inhibiting crystal growth. Since promotion of nucleation and inhibition of aggregation are both regarded as protective mechanisms against calcium oxalate urinary stone formation, the kringle domain on which the glycans are located is implicated in PTF1’s inhibitory activity. It is speculated that modifications in the glycosylation of urinary PTF1 in stone-formers may regulate its capacity to protect against calcium urolithiasis.
This paper references
10.1007/BF00393304
Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers
B. Hess (2004)
10.1681/ASN.2006040388
Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy.
B. Oortwijn (2006)
10.1515/CCLM.2002.163
Synergism between Urinary Prothrombin Fragment 1 and Urine: A Comparison of Inhibitory Activities in Stone-Prone and Stone-Free Population Groups
D. Webber (2002)
DiVerential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inXammation in IgA nephropathy
BD Oortwijn (2006)
Effects of Tamm-Horsfall Protein and Albumin on Calcium Oxalate Crystallization and Importance of Sialic Acids
陳汶吉 (2001)
Methods for the study of calcium oxalate crystallisation and their application to urolithiasis research.
Kavanagh Jp (1992)
10.1159/000058451
Influence of Urinary Sialic Acid on Calcium Oxalate Crystal Formation
E. Konya (2002)
10.1038/ki.1997.93
Relationship between supersaturation and crystal inhibition in hypercalciuric rats.
J. Asplin (1997)
10.2741/1347
Modulators of urinary stone formation.
S. Khan (2004)
10.1038/ki.1978.53
Physicochemical aspects of urolithiasis.
B. Finlayson (1978)
Sialylation of urinary prothrombin fragment 1 is diVerent in controls and stone-formers and in white and black population groups
D Webber (2006)
10.1038/ki.1975.23
Effect of diphosphonate on crystallization of calcium oxalate in vitro.
C. Pak (1975)
Where and how does urinary stone disease start? In: van Reen R (ed) Idiopathic urinary bladder
B Finlayson (1977)
10.1111/j.1749-6632.1995.tb44635.x
Osteopontin and related phosphorylated sialoproteins: effects on mineralization.
A. Boskey (1995)
10.1159/000080262
Macromolecules and Urolithiasis: Parallels and Paradoxes
R. Ryall (2004)
10.1007/978-1-4613-4295-3_97
Idiopathic Urinary Bladder Stone Disease
R. Reen (1978)
10.1007/s002400000164
The reappraisal of nephrocalcin – its role in the inhibition of calcium oxalate crystal growth and interaction with divalent metal ions
Li-Chi Chang (2001)
10.1016/J.BBAGEN.2005.02.014
The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for non-specific interactions.
R. Walton (2005)
10.1007/BF00541903
Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers
F. Atmani (2004)
Role of inhibitors and promoters of crystal nucleation , growth and aggregation in the formation of calcium stones
H Fleisch (1990)
10.1042/CS1020425
Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity.
P. Grover (2002)
10.1038/ki.1978.54
Inhibitors and promoters of stone formation.
H. Fleisch (1978)
Methods for the study of calcium oxalate crystallisation and their application to urolithiasis research.
J. P. Kavanagh (1992)
Renal Tract Stone: Metabolic Basis and Clinical Practice
J. A. Wickham (1990)
10.1007/s00240-005-0015-3
Supersaturation and renal precipitation: the key to stone formation?
J. P. Kavanagh (2005)
10.1089/109153601750124186
Effects of Tamm-Horsfall protein and albumin on calcium oxalate crystallization and importance of sialic acids.
W. Chen (2001)
10.1042/cs0890533
The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro.
R. Ryall (1995)
10.1093/GLYCOB/CWM002
Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer.
S. Barrabés (2007)
10.1038/ki.1990.7
Crystal agglomeration is a major element in calcium oxalate urinary stone formation.
D. Kok (1990)
10.1016/S0022-5347(17)43613-5
Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid.
Y. Nakagawa (1987)
10.1016/J.BBADIS.2006.03.009
Abnormal glycosylation with hypersialylated O-glycans in patients with Sialuria.
S. Wopereis (2006)
10.1046/J.1432-1327.1998.2530637.X
Inhibition of growth and aggregation of calcium oxalate crystals in vitro--a comparison of four human proteins.
P. Grover (1998)
10.1046/J.1432-1327.1999.00448.X
Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity.
P. Grover (1999)
10.1046/J.1464-410X.1997.00366.X
Effects of Tamm-Horsfall protein with normal and reduced sialic acid content upon the crystallization of calcium phosphate and calcium oxalate in human urine.
P. Hallson (1997)
10.1007/s00223-004-1288-1
Importance of Phosphorylation for Osteopontin Regulation of Biomineralization
A. Gericke (2004)
10.1111/j.1365-2141.1984.tb06106.x
Quantitation of prothrombin activation products in human urine
A. Bezeaud (1984)
Where and how does urinary stone disease start ?
B Finlayson (1977)
10.1111/j.1742-4658.2006.05314.x
Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation
D. Webber (2006)



This paper is referenced by
10.1016/j.jprot.2008.06.003
Evaluation of a standardized method of protein purification and identification after discovery by mass spectrometry.
L. Guerrier (2008)
10.1007/s00240-013-0604-5
Alteration of urinary macromolecules by adsorption on surfaces, probably an important factor in urolithiasis
Johannes M Baumann (2013)
10.1021/acs.jproteome.6b00952
The PeptideAtlas of the Domestic Laying Hen.
James P. McCord (2017)
10.1007/s11255-018-1849-2
Prevalence, pathophysiological mechanisms and factors affecting urolithiasis
Aslam Khan (2018)
10.1155/2013/360142
Stabilization of Submicron Calcium Oxalate Suspension by Chondroitin Sulfate C May Be an Efficient Protection from Stone Formation
Jun-jun Li (2013)
10.1007/s00240-008-0145-5
11th International Symposium on Urolithiasis, Nice, France, 2–5 September 2008
Ichiro Yoshioka (2008)
10.1007/978-1-84800-362-0_32
Crystallization and Other Studies
Dirk Jan Kok (2010)
10.1371/journal.pone.0045533
Association between Human Prothrombin Variant (T165M) and Kidney Stone Disease
Nanyawan Rungroj (2012)
10.1016/j.juro.2015.12.077
Assessment of Urinary Inhibitor or Promoter Activity in Uric Acid Nephrolithiasis.
S. Doizi (2016)
10.1155/2012/175843
New Pathophysiological Aspects of Growth and Prevention of Kidney Stones
Johannes M Baumann (2012)
10.1007/s00240-011-0382-x
Aggregation of freshly precipitated calcium oxalate crystals in urine of calcium stone patients and controls
Johannes M Baumann (2011)
10.4028/WWW.SCIENTIFIC.NET/AMR.952.38
Influence of Chondroitin Sulfate A on Zeta Potential, Aggregation and Sedimentation of Nano COM and Nano COD Crystallites
Lan Qing Deng (2014)
10.4028/WWW.SCIENTIFIC.NET/AMR.1052.273
Inhibition of Potassium Citrate on Aggregation of Nano Calcium Oxalate Crystal in Four Different Systems
Xiao Ling Wen (2014)
10.1002/bit.26317
Production and characterization of active recombinant human factor II with consistent sialylation
J. Lee (2017)
10.1007/s00240-019-01117-1
Potential thermodynamic and kinetic roles of phytate as an inhibitor of kidney stone formation: theoretical modelling and crystallization experiments
Saajidah Fakier (2019)
10.1016/j.urology.2010.07.494
Prothrombin haplotype associated with kidney stone disease in Northeastern Thai patients.
N. Rungroj (2011)
10.5772/INTECHOPEN.70598
The Way from Renal Calcifications and Urinary Crystals to Kidney Stones: An Important Aspect in the Pathogenesis of Calcium Nephrolithiasis
Johannes M Baumann (2017)
10.1097/MNH.0000000000000330
Molecular modifiers of kidney stones
Bryan G. Alamani (2017)
10.1007/978-1-84800-362-0_4
The Possible Roles of Inhibitors, Promoters, and Macromolecules in the Formation of Calcium Kidney Stones
R. Ryall (2010)
Semantic Scholar Logo Some data provided by SemanticScholar